Vyvanse
Vyvanse Official FDA information, side effects and uses.
Posted by Vyvanse (Vyvanse) on Tue, 21 Aug 2007 23:24:28 +0000
PHILADELPHIA, July 27 /PRNewswire-FirstCall/ -- Shire plc ( Nachrichten ) (LSE: SHP; NASDAQ: SHPGY; TSX: SHQ) announced today that VYVANSE (lisdexamfetamine dimesylate), a new once-daily medication approved to treat the symptoms of Attention Deficit Hyperactivity Disorder (ADHD), is now available in U.S. pharmacies nationwide.
Shire ups revenue forecast as new drugs shine (Reuters.co.uk)
LONDON (Reuters) - Shire nudged up its 2007 revenue growth forecast on Thursday, boosted by a string of drug launches, and said its biggest new hope, Vyvanse for hyperactivity, had made a particularly strong start.
Shire's Got Focus: Fool by Numbers (The Motley Fool)
Fast facts the Fool way.
Shire Reports $1.81 Billion Loss After Acquisition (Update1) (Bloomberg.com)
July 26 (Bloomberg) -- Shire Plc, the U.K.'s third-largest drugmaker, reported a second-quarter loss after the company wrote down assets acquired in the purchase of New River Pharmaceuticals Inc. The company raised its forecast for revenue growth this year.
Shire eyes regenerative surgery market (Daily Telegraph)
Shire, the UK's third biggest drugs maker, wants to expand its footprint in the "regenerative surgery" market after striking a licensing deal over a scar repair drug last month.
